-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $414

Benzinga·01/22/2026 14:13:21
Listen to the news
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $398 to $414.